Reported Sunday, Crinetics Presents Up To Two-Year PATHFNDR Open-Label Extension Data At ENDO 2026 Confirming PALSONIFY Maintains Stable IGF-1 Levels And Acromegaly Symptom Control

CRINETICS PHARMACEUTICALS, INC.

CRINETICS PHARMACEUTICALS, INC.

CRNX

0.00
  • Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms
  • Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks
  • Additional ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and cabergoline combination improves biochemical control of acromegaly
     
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.